 |
BREAKING:
Multibillion-Dollar Medical Marijuana Industry Is Setting the Stage for a Drug-Crisis Takeover
Dear Profit Alerts Member,
These microscopic compounds are reshaping the face of the pharmaceutical industry.
From your local pharmacy straight to the New York Stock Exchange, this new branch of pharmaceuticals is set to fuel a multibillion-dollar takeover.
 They're called cannabinoids...
And if you know how to playthis evolving industry with precision, this medical advancement could mean money in your pocket.
At the same time, you could contribute to the solution to one of America's most detrimental crises...
The opioid epidemic.
Sadly, opioid addiction and chronic pain go hand in hand.
But now, there may be an alternative.
Just take a look at some of the cold, hard facts.
According to a Harvard study, opioid prescriptions fell by 2.21 million daily doses filled per year during first rounds of state-wide legalization.
And when medical marijuana dispensaries began popping up across the nation, opioid prescriptions fell by 3.74 million daily doses per year.
The future of pharmaceuticals is here now, and it's preparing to stay.
Right now, there are well over 443 cannabis stocks actively trading...
But here at the National Institute for Cannabis Investors, we patented a tool that folks can use to spot the best ones -no matter how packed the field becomes.
This simple, three-step process can translate to a six-figure edge.
Sincerely,
Mike Ward
Co-Founder, National Institute for Cannabis Investors
P.S. The pharmaceutical industry is step 1 - but that's the just the start. The next phase could seep into the biotech industry... and if the world's richest companies begin sinking their claws into this small niche sector, it could unleash Big Pharma's biggest nightmare...
|
To unsubscribe from Money Morning Profit Alerts emails click here.
© 2019 Money Morning All Rights Reserved.
Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice.
We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any recommendations in this letter should be made only after consulting with your financial adviser and only after reviewing the prospectus or financial statements of the company.
Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Money Morning. 1125 N Charles Street, Baltimore MD 21201.
To read our privacy policy click here. To contact Customer Service click here.
|
|
